# SELLAS Life Sciences Group, Inc.: financial statements, quarterly

SLS · Nasdaq · CIK 1390478 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sls.md) · [Financials](/companies/sls/financials.md) · [Filings](/companies/sls/filings.md) · [Insiders](/companies/sls/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sls/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001390478-23-000024.md) | [0.0 d](/filings/0001390478-24-000004.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | [0.0](/filings/0001390478-24-000021.md) | [0.0 d](/filings/0001390478-25-000003.md) | [0.0](/filings/0001390478-25-000008.md) | [0.0](/filings/0001390478-25-000016.md) | [0.0](/filings/0001390478-25-000020.md) | [0.0 d](/filings/0001390478-26-000003.md) | [0.0](/filings/0001390478-26-000008.md) | [0.0](/filings/0001390478-25-000016.md) | [0.0](/filings/0001390478-25-000020.md) | [0.0 d](/filings/0001390478-26-000003.md) | [0.0](/filings/0001390478-26-000008.md) | [0.0 d](/filings/0001390478-26-000012.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [3.5](/filings/0001390478-24-000021.md) | [3.1 d](/filings/0001390478-25-000003.md) | [4.5](/filings/0001390478-25-000008.md) | [2.4](/filings/0001390478-25-000016.md) | [3.0](/filings/0001390478-25-000020.md) | [2.5 d](/filings/0001390478-26-000003.md) | [2.9](/filings/0001390478-25-000008.md) | [3.0](/filings/0001390478-25-000016.md) | [2.9](/filings/0001390478-25-000020.md) | [3.5 d](/filings/0001390478-26-000003.md) | not reported | not reported |
| Operating income | $m | [(9.4)](/filings/0001390478-24-000021.md) | [(8.2) d](/filings/0001390478-25-000003.md) | [(9.6)](/filings/0001390478-25-000008.md) | [(7.6)](/filings/0001390478-25-000016.md) | [(7.3)](/filings/0001390478-25-000020.md) | [(6.9) d](/filings/0001390478-26-000003.md) | [(6.1)](/filings/0001390478-26-000008.md) | [(6.9)](/filings/0001390478-26-000012.md) | [(7.1)](/filings/0001390478-25-000020.md) | [(8.3) d](/filings/0001390478-26-000003.md) | [(9.3)](/filings/0001390478-26-000008.md) | [(10.6)](/filings/0001390478-26-000012.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(9.3)](/filings/0001390478-24-000021.md) | [(8.1) d](/filings/0001390478-25-000003.md) | [(9.6)](/filings/0001390478-25-000008.md) | [(7.5)](/filings/0001390478-25-000016.md) | [(7.1)](/filings/0001390478-25-000020.md) | [(6.7) d](/filings/0001390478-26-000003.md) | [(5.8)](/filings/0001390478-26-000008.md) | [(6.6)](/filings/0001390478-26-000012.md) | [(6.8)](/filings/0001390478-25-000020.md) | [(7.7) d](/filings/0001390478-26-000003.md) | [(8.4)](/filings/0001390478-26-000008.md) | [(9.6)](/filings/0001390478-26-000012.md) |
| Diluted EPS | $ per share | [(0.33)](/filings/0001390478-24-000021.md) | not reported | [(0.21)](/filings/0001390478-25-000008.md) | [(0.13)](/filings/0001390478-25-000016.md) | [(0.10)](/filings/0001390478-25-000020.md) | not reported | [(0.07)](/filings/0001390478-26-000008.md) | [(0.07)](/filings/0001390478-26-000012.md) | [(0.06)](/filings/0001390478-25-000020.md) | not reported | [(0.05)](/filings/0001390478-26-000008.md) | [(0.05)](/filings/0001390478-26-000012.md) |
| Basic EPS | $ per share | [(0.33)](/filings/0001390478-24-000021.md) | not reported | [(0.21)](/filings/0001390478-25-000008.md) | [(0.13)](/filings/0001390478-25-000016.md) | [(0.10)](/filings/0001390478-25-000020.md) | not reported | [(0.07)](/filings/0001390478-26-000008.md) | [(0.07)](/filings/0001390478-26-000012.md) | [(0.06)](/filings/0001390478-25-000020.md) | not reported | [(0.05)](/filings/0001390478-26-000008.md) | [(0.05)](/filings/0001390478-26-000012.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.0](/filings/0001390478-23-000024.md) | [2.5](/filings/0001390478-25-000003.md) | [18.4](/filings/0001390478-24-000010.md) | [9.1](/filings/0001390478-24-000015.md) | [21.0](/filings/0001390478-24-000021.md) | [13.9](/filings/0001390478-26-000003.md) | [28.4](/filings/0001390478-25-000008.md) | [25.3](/filings/0001390478-25-000016.md) | [44.3](/filings/0001390478-25-000020.md) | [71.8](/filings/0001390478-26-000012.md) | [107](/filings/0001390478-26-000008.md) | [138](/filings/0001390478-26-000012.md) |
| Current assets | $m | [5.2](/filings/0001390478-23-000024.md) | [3.2](/filings/0001390478-25-000003.md) | [21.5](/filings/0001390478-24-000010.md) | [12.3](/filings/0001390478-24-000015.md) | [24.0](/filings/0001390478-24-000021.md) | [16.3](/filings/0001390478-26-000003.md) | [32.0](/filings/0001390478-25-000008.md) | [29.4](/filings/0001390478-25-000016.md) | [49.1](/filings/0001390478-25-000020.md) | [75.2](/filings/0001390478-26-000012.md) | [111](/filings/0001390478-26-000008.md) | [143](/filings/0001390478-26-000012.md) |
| Total assets | $m | [8.1](/filings/0001390478-23-000024.md) | [6.2](/filings/0001390478-25-000003.md) | [24.4](/filings/0001390478-24-000010.md) | [15.1](/filings/0001390478-24-000015.md) | [26.5](/filings/0001390478-24-000021.md) | [19.4](/filings/0001390478-26-000003.md) | [35.0](/filings/0001390478-25-000008.md) | [32.3](/filings/0001390478-25-000016.md) | [51.6](/filings/0001390478-25-000020.md) | [78.3](/filings/0001390478-26-000012.md) | [114](/filings/0001390478-26-000008.md) | [145](/filings/0001390478-26-000012.md) |
| Current liabilities | $m | [11.7](/filings/0001390478-23-000024.md) | [13.7](/filings/0001390478-25-000003.md) | [14.4](/filings/0001390478-24-000010.md) | [12.0](/filings/0001390478-24-000015.md) | [10.6](/filings/0001390478-24-000021.md) | [9.5](/filings/0001390478-26-000003.md) | [6.9](/filings/0001390478-25-000008.md) | [6.0](/filings/0001390478-25-000016.md) | [5.9](/filings/0001390478-25-000020.md) | [7.0](/filings/0001390478-26-000012.md) | [6.5](/filings/0001390478-26-000008.md) | [7.6](/filings/0001390478-26-000012.md) |
| Total liabilities | $m | [11.9](/filings/0001390478-23-000024.md) | [14.2](/filings/0001390478-25-000003.md) | [14.8](/filings/0001390478-24-000010.md) | [12.2](/filings/0001390478-24-000015.md) | [10.6](/filings/0001390478-24-000021.md) | [10.0](/filings/0001390478-26-000003.md) | [7.2](/filings/0001390478-25-000008.md) | [6.2](/filings/0001390478-25-000016.md) | [5.9](/filings/0001390478-25-000020.md) | [7.5](/filings/0001390478-26-000012.md) | [6.8](/filings/0001390478-26-000008.md) | [7.7](/filings/0001390478-26-000012.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(3.8)](/filings/0001390478-24-000021.md) | [(8.0)](/filings/0001390478-26-000003.md) | [9.7](/filings/0001390478-25-000016.md) | [2.9](/filings/0001390478-25-000020.md) | [15.9](/filings/0001390478-25-000020.md) | [9.5](/filings/0001390478-26-000012.md) | [27.8](/filings/0001390478-26-000012.md) | [26.1](/filings/0001390478-26-000012.md) | [45.6](/filings/0001390478-25-000020.md) | [70.9](/filings/0001390478-26-000012.md) | [107](/filings/0001390478-26-000012.md) | [138](/filings/0001390478-26-000012.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.9) d](/filings/0001390478-24-000021.md) | [(4.8) d](/filings/0001390478-25-000003.md) | [(10.8)](/filings/0001390478-25-000008.md) | [(9.7) d](/filings/0001390478-25-000016.md) | [(7.8) d](/filings/0001390478-25-000020.md) | [(7.2) d](/filings/0001390478-26-000003.md) | [(9.1)](/filings/0001390478-26-000008.md) | [(7.3) d](/filings/0001390478-26-000012.md) | [(7.1) d](/filings/0001390478-25-000020.md) | [(4.9) d](/filings/0001390478-26-000003.md) | [(8.8)](/filings/0001390478-26-000008.md) | [(7.6) d](/filings/0001390478-26-000012.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.6](/filings/0001390478-23-000024.md) | [23.5](/filings/0001390478-24-000010.md) | [28.3](/filings/0001390478-24-000015.md) | [28.4](/filings/0001390478-24-000021.md) | [44.8](/filings/0001390478-25-000008.md) | [57.6](/filings/0001390478-25-000016.md) | [68.3](/filings/0001390478-25-000020.md) | [87.8](/filings/0001390478-26-000008.md) | [98.6](/filings/0001390478-26-000012.md) | [108](/filings/0001390478-25-000020.md) | [172](/filings/0001390478-26-000008.md) | [189](/filings/0001390478-26-000012.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 201,945,709 at 2026-08-10, from the cover of the [10-Q filed 2026-08-11](/filings/0001390478-26-000012.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.